Literature DB >> 17631279

Mechanism of acridine-based telomerase inhibition and telomere shortening.

Mekala Gunaratnam1, Olga Greciano, Cristina Martins, Anthony P Reszka, Christoph M Schultes, Hamid Morjani, Jean-Francois Riou, Stephen Neidle.   

Abstract

The trisubstituted acridine compound BRACO-19 has been developed as a ligand for stabilising G-quadruplex structures. It is shown here that BRACO-19 produces short- and long-term growth arrest in cancer cell lines, and is significantly less potent in a normal cell line. BRACO-19 reduces telomerase activity and long-term telomere length attrition is observed. It is also shown that BRACO-19 binds to telomeric single-stranded overhang DNA, consistent with quadruplex formation, and the single-stranded protein hPOT1 has been shown to be displaced from the overhang in vitro and in cellular experiments. It is concluded that the cellular activity of BRACO-19 can be ascribed both to the uncapping of 3' telomere ends and to telomere shortening that may preferentially affect cells with short telomeres.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17631279     DOI: 10.1016/j.bcp.2007.06.011

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  22 in total

1.  First International Meeting on Quadruplex DNA.

Authors:  W David Wilson; Hiroshi Sugiyama
Journal:  ACS Chem Biol       Date:  2007-09-21       Impact factor: 5.100

2.  Rational design of substituted diarylureas: a scaffold for binding to G-quadruplex motifs.

Authors:  William C Drewe; Rupesh Nanjunda; Mekala Gunaratnam; Monica Beltran; Gary N Parkinson; Anthony P Reszka; W David Wilson; Stephen Neidle
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

3.  The nickel(II) complex of guanidinium phenyl porphyrin, a specific G-quadruplex ligand, targets telomeres and leads to POT1 mislocalization in culture cells.

Authors:  Laurent Sabater; Marie-Laure Nicolau-Travers; Aurore De Rache; Enora Prado; Jérôme Dejeu; Oriane Bombarde; Joris Lacroix; Patrick Calsou; Eric Defrancq; Jean-Louis Mergny; Dennis Gomez; Geneviève Pratviel
Journal:  J Biol Inorg Chem       Date:  2015-04-07       Impact factor: 3.358

4.  Mechanism of the antiproliferative activity of some naphthalene diimide G-quadruplex ligands.

Authors:  Sonja M Hampel; Antonella Pepe; Karin M Greulich-Bode; Sanjay V Malhotra; Anthony P Reszka; Sebastian Veith; Petra Boukamp; Stephen Neidle
Journal:  Mol Pharmacol       Date:  2012-11-27       Impact factor: 4.436

5.  A small molecule inhibitor of Pot1 binding to telomeric DNA.

Authors:  Sarah E Altschuler; Johnny E Croy; Deborah S Wuttke
Journal:  Biochemistry       Date:  2012-09-26       Impact factor: 3.162

6.  Modelling the regulation of telomere length: the effects of telomerase and G-quadruplex stabilising drugs.

Authors:  Bartholomäus V Hirt; Jonathan A D Wattis; Simon P Preston
Journal:  J Math Biol       Date:  2013-04-26       Impact factor: 2.259

7.  Formation of a unique end-to-end stacked pair of G-quadruplexes in the hTERT core promoter with implications for inhibition of telomerase by G-quadruplex-interactive ligands.

Authors:  SunMi L Palumbo; Scot W Ebbinghaus; Laurence H Hurley
Journal:  J Am Chem Soc       Date:  2009-08-12       Impact factor: 15.419

8.  G-quadruplex nucleic acids as therapeutic targets.

Authors:  Shankar Balasubramanian; Stephen Neidle
Journal:  Curr Opin Chem Biol       Date:  2009-06-08       Impact factor: 8.822

9.  Targeting human gastrointestinal stromal tumor cells with a quadruplex-binding small molecule.

Authors:  Mekala Gunaratnam; Stephen Swank; Shozeb M Haider; Katja Galesa; Anthony P Reszka; Monica Beltran; Francisco Cuenca; Jonathan A Fletcher; Stephen Neidle
Journal:  J Med Chem       Date:  2009-06-25       Impact factor: 7.446

Review 10.  Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?

Authors:  Shankar Balasubramanian; Laurence H Hurley; Stephen Neidle
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.